Aurinia Pharmaceuticals Quarterly Income Statement
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aurinia Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Aurinia Pharmaceuticals generated $83.2 million in revenue, up 18.9% from the same quarter a year earlier. Net income was $37.4 million (+73.9% year over year), for a net margin of 45.0% versus a median of 42.9% in the prior 5 quarters. Gross margin was 92.1% (up from 89.8%) and operating margin 55.7%.
Diluted earnings per share came in at $0.28, up from $0.16.
Summary generated from market data by MetaCap's automated system. Methodology
Aurinia Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.22M | 77.70M | 77.11M | 73.47M | 70.01M | 62.47M | 59.87M | 67.77M | 57.19M | 50.30M | 45.09M | 54.52M |
| Revenue growth (YoY) | +18.87% | +24.40% | +28.81% | +8.41% | +22.41% | +24.18% | +32.76% | +24.32% | +37.83% | +46.19% | +58.59% | -2.27% |
| Cost of Revenue | 6.55M | 6.50M | 8.80M | 8.18M | 7.12M | 8.57M | 5.55M | 6.04M | 8.91M | 7.75M | 5.39M | 6.77M |
| Gross Profit | 76.67M | 71.20M | 68.31M | 65.29M | 62.89M | 53.89M | 54.31M | 61.74M | 48.28M | 42.55M | 39.70M | 47.75M |
| Operating Expenses | 30.32M | 29.78M | 43.88M | 43.72M | 49.92M | 40.62M | 61.54M | 56.02M | 58.70M | 63.56M | 74.77M | 70.78M |
| Research & Development | 13.05M | 7.47M | 10.89M | 8.44M | 7.43M | 5.74M | 8.11M | 3.05M | 4.08M | 5.55M | 10.23M | 13.61M |
| Operating Income | 46.34M | 41.42M | 33.24M | 29.75M | 20.08M | 21.85M | -1.67M | 11.75M | -1.51M | -13.25M | -29.67M | -16.26M |
| Interest Expense | 948.00K | 1.01M | 1.05M | 1.10M | 1.12M | 1.07M | 1.15M | 1.21M | 1.20M | 1.28M | 1.31M | 1.40M |
| Pretax Income | 48.79M | 43.92M | 35.69M | 31.96M | 22.16M | 24.35M | 1.17M | 14.81M | 1.48M | -10.01M | -26.42M | -13.15M |
| Income Tax | 11.37M | 9.57M | -175.10M | 411.00K | 643.00K | 1.00M | -256.00K | 457.00K | 756.00K | 739.00K | 459.00K | 298.00K |
| Net Income | 37.41M | 34.35M | 210.79M | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M | 722.00K | -10.75M | -26.88M | -13.45M |
| Net Income growth (YoY) | +73.91% | +47.17% | +14651.15% | +119.87% | +2879.64% | — | — | — | — | — | — | — |
| EPS (Basic) | 0.29 | 0.26 | 1.60 | 0.24 | 0.16 | 0.17 | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 | -0.09 |
| EPS (Diluted) | 0.28 | 0.25 | 1.53 | 0.23 | 0.16 | 0.16 | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 | -0.09 |
| Shares Outstanding (Basic) | 130.08M | 132.38M | — | 131.81M | 134.87M | 138.92M | — | 143.05M | 143.33M | 144.01M | — | 142.85M |
| Shares Outstanding (Diluted) | 133.53M | 137.64M | — | 136.01M | 137.53M | 143.20M | — | 145.65M | 144.11M | 144.01M | — | 142.85M |
| EBITDA | 51.17M | 46.24M | 38.10M | 34.61M | 24.95M | 26.70M | 3.19M | 16.64M | 3.33M | -8.41M | -35.77M | -11.00M |
| Gross Margin | 92.12% | 91.63% | 88.59% | 88.87% | 89.84% | 86.27% | 90.73% | 91.10% | 84.42% | 84.59% | 88.04% | 87.58% |
| Operating Margin | 55.68% | 53.31% | 43.10% | 40.49% | 28.69% | 34.97% | -2.79% | 17.33% | -2.65% | -26.35% | -65.80% | -29.83% |
| Net Margin | 44.96% | 44.21% | 273.35% | 42.95% | 30.73% | 37.37% | 2.39% | 21.17% | 126.00% | -21.37% | -59.60% | -24.67% |
This table shows 12 quarterly periods of Aurinia Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AUPH's reporting calendar. What is a income statement?